Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stake Boosted by SVB Wealth LLC

SVB Wealth LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% in the 4th quarter, Holdings Channel reports. The firm owned 10,320 shares of the medical equipment provider’s stock after purchasing an additional 174 shares during the quarter. SVB Wealth LLC’s holdings in Zimmer Biomet were worth $1,256,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Oak Family Advisors LLC bought a new position in Zimmer Biomet in the fourth quarter worth about $7,866,000. Mackenzie Financial Corp lifted its holdings in shares of Zimmer Biomet by 1.2% in the 4th quarter. Mackenzie Financial Corp now owns 117,590 shares of the medical equipment provider’s stock worth $14,311,000 after purchasing an additional 1,371 shares during the last quarter. Vontobel Holding Ltd. boosted its position in Zimmer Biomet by 1.5% during the 4th quarter. Vontobel Holding Ltd. now owns 8,664 shares of the medical equipment provider’s stock valued at $1,054,000 after purchasing an additional 124 shares during the period. Lecap Asset Management Ltd. bought a new position in Zimmer Biomet during the 4th quarter worth $970,000. Finally, Louisiana State Employees Retirement System acquired a new stake in Zimmer Biomet in the fourth quarter worth $1,533,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 1.6 %

ZBH stock opened at $119.41 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The firm has a market cap of $24.53 billion, a PE ratio of 24.42, a P/E/G ratio of 2.23 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The firm has a 50 day simple moving average of $126.39 and a 200 day simple moving average of $119.10.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the firm earned $1.88 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Insider Activity

In related news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Barclays raised their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Citigroup boosted their price objective on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Raymond James raised their target price on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.